When to Start Blood Thinners During Pregnancy?

The right time to start blood thinners during pregnancy depends almost entirely on why you need them. For most women with inherited clotting disorders or a history of blood clots, low-molecular-weight heparin begins as soon as pregnancy is confirmed or even before conception. For women with mechanical heart valves, the timeline is more complex because warfarin, the drug that best protects the valve, can harm the developing baby during a specific window in early pregnancy. And for women at high risk of preeclampsia, low-dose aspirin ideally starts before the end of the first trimester. Each scenario carries its own logic, its own risks, and its own set of trade-offs that you and your doctor need to work through together.

Why Pregnancy Itself Raises Clot Risk

Your body’s clotting system shifts dramatically during pregnancy. Levels of several clotting factors, including factors VII, VIII, X, and fibrinogen, rise steadily and peak near the time of delivery. At the same time, natural anticoagulant defenses weaken: protein S activity drops, resistance to activated protein C increases, and the system that dissolves clots (fibrinolysis) slows down.¹ The net result is a state of hypercoagulability that makes clotting roughly four to ten times more likely than in a non-pregnant woman of the same age.¹ This shift is not a malfunction. It evolved to limit bleeding during and after delivery. But it also means that women who already have an underlying clotting tendency face a meaningfully higher chance of deep vein thrombosis or pulmonary embolism during pregnancy and in the weeks following birth.

These changes begin early. Thrombin generation increases, clotting times shorten, and fibrinogen levels start climbing in the first trimester.² That early onset is one reason why, for women who need anticoagulation, treatment often starts right away rather than waiting for a later stage of pregnancy.

Inherited Clotting Disorders and Risk Stratification

If you carry an inherited thrombophilia, the decision about when and how aggressively to start blood thinners hinges on two things: which specific genetic variant you have and whether you or a close family member has actually had a blood clot before. These two factors together place you into a risk category that guides treatment.

Women considered high risk, such as those with certain compound deficiencies or a personal history of clots, are typically started on treatment-dose low-molecular-weight heparin (LMWH) as soon as pregnancy is confirmed. That full-dose therapy continues throughout pregnancy and for at least six weeks after delivery.³ Women at moderate risk receive a lower, prophylactic dose of LMWH throughout pregnancy and for six weeks postpartum. Women at lower risk, who may carry a thrombophilic trait but have no personal or family clot history, may not need daily injections during pregnancy itself, but prophylactic LMWH during the six-week postpartum window, when clot risk peaks, is still recommended. Low-dose aspirin during pregnancy is sometimes considered for this low-risk group as well.³

The key point is that “when to start” is inseparable from “how much.” A woman with a high-risk inherited thrombophilia and prior clots needs to begin early and at a therapeutic dose. A woman with a milder genetic variant and no personal history may only need postpartum coverage. Your hematologist or maternal-fetal medicine specialist should map this out before or early in pregnancy, ideally at a preconception visit if one is possible.

Mechanical Heart Valves and the Warfarin Dilemma

Pregnancy with a mechanical heart valve is one of the most challenging anticoagulation scenarios in all of medicine. Mechanical valves need continuous, reliable anticoagulation to prevent life-threatening clots from forming on the valve. Warfarin does this job well, but warfarin crosses the placenta and can cause a specific pattern of birth defects known as warfarin embryopathy when the fetus is exposed between roughly 6 and 12 weeks of gestation.⁴ The defects primarily affect bone and cartilage development and occur in about 6% of live births when warfarin is used throughout pregnancy.⁵

To avoid this, many guidelines recommend switching from warfarin to LMWH (or unfractionated heparin) during the first trimester and then resuming warfarin in the second and third trimesters, when the risk of embryopathy has passed.⁶ But this switch creates its own danger. Heparin-based drugs do not protect mechanical valves as reliably as warfarin does. In systematic reviews, using warfarin throughout pregnancy carried a valve thrombosis risk of about 4%, while switching to heparin in the first trimester nearly doubled that risk to about 9%.⁵ Valve thrombosis can be fatal.

One important detail that many guidelines have historically overlooked is warfarin’s long half-life. After the last dose, it takes about a week for warfarin to be fully eliminated from the body. That means if you switch to heparin at exactly 6 weeks of gestation, warfarin is still circulating at meaningful levels well into the embryopathy-sensitive window. Some experts have argued that the substitution should begin earlier than 6 weeks to truly clear warfarin before the danger period starts.⁴ This is a conversation worth having with your cardiologist and obstetrician before conception, because the transition needs to be planned carefully.

An alternative strategy used in some centers is dose-adjusted LMWH throughout the entire pregnancy, monitored with anti-Xa levels to keep protection in the right range. Target trough anti-Xa levels of 0.6 to 0.7 and peak levels around 1.0 to 1.2 have been recommended, with some experts suggesting three-times-daily dosing to maintain more consistent levels.⁶ Yet a third approach, using low-dose warfarin (5 mg or less daily) throughout pregnancy, is sometimes considered when the required warfarin dose is small, since lower doses appear to carry less teratogenic risk. No single strategy is universally accepted, and the decision involves weighing the mother’s valve type, her prior clotting history, and how reliably she can be monitored.

Why Heparin Is the Default Drug in Pregnancy

Low-molecular-weight heparin and its older cousin, unfractionated heparin, are preferred during pregnancy for one straightforward reason: they do not cross the placenta. The heparin molecule is too large to pass through, so the fetus is not directly exposed to the drug.⁷ Research on heparin products during pregnancy has been broadly reassuring with respect to birth defects, though studies have tended to look at defects as a group rather than examining individual types in detail.

LMWH has largely replaced unfractionated heparin for most pregnant women because it can be injected once or twice a day under the skin rather than requiring a continuous IV drip, and it carries a lower risk of side effects. One concern with any heparin product used over many months is bone loss. Unfractionated heparin is more strongly linked to osteoporotic fractures during pregnancy than LMWH, so the low-molecular-weight versions are preferred when long-term use is needed.⁸ Even so, if you are on LMWH for the full duration of a pregnancy, maintaining adequate calcium and vitamin D intake is a sensible precaution to discuss with your provider.

What About Newer Oral Blood Thinners

Direct oral anticoagulants (DOACs) like rivaroxaban, apixaban, and dabigatran have transformed blood clot treatment outside of pregnancy, but they are not recommended during pregnancy. Unlike heparin, these drugs are small enough to cross the placenta, and there is limited safety data. A retrospective study looking at pregnancies exposed to DOACs, predominantly rivaroxaban, found that the available data did not suggest a high risk of embryopathy, but the reports were missing important details and the evidence base remains thin.⁹ Guidance from the International Society on Thrombosis and Haemostasis advises against terminating a pregnancy solely out of fear of DOAC exposure, recommending close surveillance instead.

A pharmacovigilance analysis found that among reported adverse events in DOAC-exposed pregnancies, a substantial proportion, more than 40%, had alternative explanations such as advanced maternal age or co-exposure to other potentially harmful medications.¹⁰ The current picture is that accidental early DOAC exposure is probably not as catastrophic as once feared, but no one should deliberately plan to use a DOAC during pregnancy when heparin alternatives exist. If you become pregnant while taking a DOAC, the standard advice is to switch to LMWH as soon as the pregnancy is confirmed.

Low-Dose Aspirin for Preeclampsia Prevention

Low-dose aspirin occupies a different category from the anticoagulants discussed above. It is not used to prevent blood clots in veins; rather, it is prescribed to reduce the risk of preeclampsia in women identified as high risk. Preeclampsia is a pregnancy-specific condition involving high blood pressure and organ damage, and it remains a major cause of maternal and fetal complications worldwide.

The timing of aspirin initiation matters. Guidelines generally recommend starting low-dose aspirin before the end of the first trimester, often around 12 to 16 weeks, in women with recognized risk factors. A study of high-risk pregnant women found that those who started aspirin early had a preeclampsia rate of about 9%, compared with roughly 29% in the control group, representing a nearly 70% relative risk reduction.¹¹ That is a large effect, and it depends heavily on starting early enough. Aspirin begun after 20 weeks shows much less benefit, which is why screening for preeclampsia risk factors during the first prenatal visit is important.

Risk factors that typically trigger the recommendation include a history of preeclampsia in a previous pregnancy, chronic high blood pressure, kidney disease, autoimmune conditions, type 1 or type 2 diabetes, and carrying multiples. Some guidelines also include advanced maternal age and obesity as contributing factors. If you have one or more of these, ask your provider about aspirin early in prenatal care rather than waiting.

Dosing Changes as Pregnancy Progresses

Pregnancy alters your body’s handling of LMWH in ways that can affect how well the drug works. Blood volume expands, kidney clearance speeds up, and body weight increases, all of which can dilute or accelerate the elimination of the drug. A single-center study found that about 55% to 69% of patients required dose adjustments over the course of pregnancy to maintain target anti-factor Xa activity.¹² The prophylactic dose in that study settled at roughly 0.6 mg/kg across all three trimesters, while therapeutic dosing hovered around 0.9 mg/kg.

Whether routine anti-Xa monitoring is actually necessary for all pregnant women on LMWH remains debated. A systematic review concluded that current evidence does not support the need for anti-Xa monitoring in pregnant women receiving prophylactic or therapeutic LMWH, because weight-based dosing strategies performed equally well in terms of both safety and effectiveness compared with anti-Xa-guided adjustments.¹³ That said, many high-risk centers still check levels periodically, particularly in women with mechanical heart valves, extreme body weights, or kidney problems, where dosing predictability is less certain.

Planning Around Delivery

One of the trickiest parts of anticoagulation in pregnancy is managing the transition around delivery. Blood thinners increase bleeding risk during labor, and epidural or spinal anesthesia cannot safely be placed if anticoagulant levels are too high. That means the last dose of LMWH has to be timed carefully so the drug clears your system before delivery begins, with the exact interval depending on whether you are on a prophylactic or therapeutic dose.

For women on therapeutic anticoagulation who cannot tolerate any break in coverage, such as those with mechanical heart valves, a common approach is to switch from LMWH to an intravenous unfractionated heparin drip in the days or weeks before the expected delivery date. Unfractionated heparin has a much shorter half-life and can be stopped and reversed more quickly if labor starts or a cesarean is needed.¹⁴ However, this switch comes with the inconvenience of hospitalization and continuous IV access.

For women on prophylactic doses, the peripartum transition may be simpler. A study comparing women who continued LMWH up to delivery with those who switched to unfractionated heparin found no significant difference in the type of anesthesia received or in the rate of bleeding complications.¹⁵ Continuing LMWH at prophylactic doses, with careful timing of the last injection before delivery, may be a reasonable option for lower-risk patients. This needs to be coordinated with the anesthesia team so everyone knows when the last dose was given and when an epidural or spinal can safely be placed.

Restarting After Delivery

For most women who need anticoagulation, the postpartum period carries its own set of risks. The hypercoagulable changes of pregnancy do not disappear the moment the baby is born; clotting risk remains elevated for several weeks. At the same time, the immediate postpartum hours carry a higher bleeding risk, especially after a cesarean section. Restarting anticoagulation is a balancing act between these two dangers.

In general, prophylactic LMWH is restarted within 6 to 12 hours after a vaginal delivery and within 12 to 24 hours after a cesarean section, as long as bleeding is controlled. Women who were on therapeutic doses may face a slightly longer delay, and the decision is individualized based on surgical bleeding, wound status, and the urgency of the anticoagulation indication. For women with mechanical heart valves, the goal is to resume anticoagulation as quickly as safely possible and to bridge with heparin until warfarin reaches a therapeutic level, typically over several days.

If you were taking warfarin before pregnancy and plan to resume it afterward, both warfarin and LMWH are considered compatible with breastfeeding. Warfarin does not pass into breast milk in clinically significant amounts. As for the newer DOACs, emerging data suggest that rivaroxaban transfers into breast milk at low levels, with relative infant doses below the threshold generally considered safe.¹⁶ Apixaban showed higher milk transfer, with relative infant doses above the typical safety cutoff in some studies, making its use during breastfeeding less well established. More data are needed before DOACs can be routinely recommended in breastfeeding mothers, but the early findings are cautiously encouraging for some agents.

Heparin and Aspirin for Fertility Treatment

One area where blood thinners are sometimes used during early pregnancy, or even around the time of embryo transfer, is in women undergoing in vitro fertilization who have had repeated implantation failures. The theory is that improving blood flow to the uterine lining could help embryos implant. Some women with antiphospholipid antibodies or antinuclear antibodies are offered heparin and low-dose aspirin around the time of IVF.

The evidence for this practice is not encouraging. A randomized, double-blind, placebo-controlled trial of heparin and aspirin in women with IVF implantation failure and positive antiphospholipid or antinuclear antibodies found no significant difference in pregnancy rates or implantation rates compared with placebo.¹⁷ Implantation rates were nearly identical between the treatment and placebo groups. Despite this, the practice persists in some clinics, often driven by desperation and a desire to try anything that might help. If your fertility specialist recommends this combination, it is worth asking about the evidence and understanding that the best available trial did not show a benefit.

This is distinct from the well-established use of heparin and aspirin in women with antiphospholipid syndrome and recurrent pregnancy loss (not implantation failure), where anticoagulation during pregnancy has stronger supporting evidence. The distinction between these two clinical scenarios matters and is sometimes blurred in practice.

1
Thrombosis Research. Haemostatic changes in pregnancy
2
PubMed. Hemostasis during normal pregnancy and puerperium
3
PubMed. Inherited thrombophilias and anticoagulation in pregnancy
4
PubMed. The “warfarin window” in pregnancy: the importance of half-life
5
PubMed. Anticoagulation of pregnant women with mechanical heart valves: a systematic review of the literature
6
PubMed Central. Anticoagulation for mechanical heart valves during pregnancy: A case report and a literature review
7
PubMed Central. Maternal exposure to heparin products and risk of birth defects in the National Birth Defects Prevention Study
8
PubMed. Minimising the risk of heparin-induced osteoporosis during pregnancy
9
PubMed. Safety of direct oral anticoagulant exposure during pregnancy: a retrospective cohort study
10
Scientific Reports. Direct-acting oral anticoagulants (DOACs) in pregnancy: new insight from VigiBase®
11
Scientific Reports. Early initiation of low-dose aspirin for the prevention of pre-eclampsia in high-risk pregnancies
12
PubMed Central. Dosing and Monitoring of Low Molecular Weight Heparin in High-Risk Pregnancy: Single Center Experience
13
PubMed. Anti-Xa Monitoring of Low-Molecular-Weight Heparin during Pregnancy: A Systematic Review
14
PubMed. Managing anticoagulation peripartum
15
PubMed. Comparison of Continuation of Low-Molecular-Weight Heparin versus Switching to Unfractionated Heparin in the Peripartum
16
PubMed Central. The safety of direct oral anticoagulants use during lactation: A systematic review
17
PubMed. A randomized, double-blind, placebo-controlled trial of heparin and aspirin for women with in vitro fertilization implantation failure and antiphospholipid or antinuclear antibodies